AQUESTIVE THERAPEUTICS INC. - COMMON STOCK

Aquestive Therapeutics Provides Business Update and Outlines Key 2023 Objectives

06 Jan 2023 07:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Announces Completion of FDA End-of-Phase 2 Meeting For AQST-109 (epinephrine sublingual film)

22 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Announces Publication of Crossover Food Effect Study of Diazepam Nasal Spray in Epilepsia

29 Nov 2022 07:00:02 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

15 Nov 2022 07:00:02 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic Studies for AQST-109 (epinephrine sublingual film) at American Academy of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting

09 Nov 2022 15:34:06 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

01 Nov 2022 15:01:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Licenses Sympazan® (clobazam) Oral Film to Assertio Holdings, Inc.

27 Oct 2022 08:05:24 By Nasdaq GlobeNewswire

Aquestive Therapeutics Announces Positive Decision in States’ Suboxone Antitrust Lawsuit on All Claims

24 Oct 2022 07:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Report Third Quarter 2022 Financial Results and Recent Business Highlights on November 1 and Host Conference Call on November 2 at 8:00 a.m. ET

19 Oct 2022 07:00:02 By Nasdaq GlobeNewswire

Aquestive Therapeutics Receives Positive FDA Written Response for AQST-109 Epinephrine Sublingual Film

11 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Aquestive Therapeutics Enters License and Supply Agreement with Pharmanovia for Libervant™ (diazepam) Buccal Film for European and MENA Markets

28 Sep 2022 07:00:01 By Nasdaq GlobeNewswire

Aquestive Therapeutics Announces Positive EPIPHAST II Trial Data for AQST-109 When Compared to EpiPen®

27 Sep 2022 06:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Announces Expert Allergy Scientific Advisory Board

12 Sep 2022 15:01:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Participate in Two Investor Conferences in September

31 Aug 2022 15:02:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Receives FDA Tentative Approval for Libervant™ (diazepam) Buccal Film

31 Aug 2022 07:00:01 By Nasdaq GlobeNewswire

Aquestive Therapeutics Strengthens Team to Align with Strategic Focus on Allergy Space

10 Aug 2022 15:50:35 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

02 Aug 2022 15:02:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Participate in Wedbush PacGrow Healthcare Conference

26 Jul 2022 07:00:01 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Report Second Quarter 2022 Financial Results and Recent Business Highlights on August 2 and Host Conference Call on August 3 at 8:00 a.m. ET

20 Jul 2022 07:00:01 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reports Positive Results from Final Two Arms of EPIPHAST Trial Supporting Performance and Real-World Functionality of AQST-109 Epinephrine Oral Film

11 Jul 2022 07:00:01 By Nasdaq GlobeNewswire